Skip to content

Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients

Risk Stratification for Hospital-Acquired Venous Thromboembolism in Medical Patients: a Prospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04439383
Acronym
RISE
Enrollment
1353
Registered
2020-06-19
Start date
2020-06-22
Completion date
2022-04-01
Last updated
2022-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis, Embolism and Thrombosis, Hospital Acquired Condition, Mobility Limitation, Pulmonary Embolism, Venous Thromboembolism, Venous Thromboses

Keywords

Venous thromboembolism, Pulmonary embolism, Deep vein thrombosis, Risk factor, Hospital-acquired, Mobility, Accelerometry

Brief summary

Hospital-acquired venous thromboembolism (HA-VTE) is one of the leading preventable causes of in-hospital mortality, but prevention of VTE in hospitalized medical patients remains challenging, as preventive measures such as pharmacological thromboprophylaxis (TPX) need to be tailored to individual thrombotic risk. The broad objective of this project is to improve VTE prevention strategies in hospitalized medical patients by prospectively examining VTE risk factors (including mobility) and comparing existing risk assessment models.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire Vaudois
CollaboratorOTHER
University Hospital, Geneva
CollaboratorOTHER
University of Bern
CollaboratorOTHER
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Admitted for hospitalization \>24 hours on a general internal medicine ward * Informed consent as documented by signature

Exclusion criteria

* Need for therapeutic anticoagulation (e.g., atrial fibrillation) * Life expectancy \<30 days * Insufficient proficiency of the German or French language * Unwilling to provide informed consent * Prior enrolment in the study

Design outcomes

Primary

MeasureTime frameDescription
Venous thromboembolismWithin 90 days of initial hospital admissionSymptomatic, objectively confirmed fatal and non-fatal hospital-acquired venous thromboembolism, including symptomatic distal and proximal deep vein thrombosis and pulmonary embolism after hospital admission

Secondary

MeasureTime frameDescription
All-cause mortalityDuring hospitalization (an average of 7 days) and up to 90 days of initial hospital admissionAll-cause mortality (all causes of death will be considered)
Major bleedingDuring hospitalization (an average of 7 days) and up to 90 days of initial hospital admissionMajor bleeding will be defined as fatal bleeding, symptomatic bleeding at critical sites (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome), or bleeding with a reduction of hemoglobin of at least 20 g/L or bleeding leading to transfusion of 2 or more units of packed red blood cells according to the definition of the International Society on Thrombosis and Haemostasis
Clinically relevant non-major bleedingDuring hospitalization (an average of 7 days) and up to 90 days of initial hospital admissionClinically relevant non-major bleeding, defined as overt bleeding that does not meet criteria for major bleeding but is associated with a medical intervention, unscheduled physician contact (visit or telephone call), or pain or impairment of activities of daily life
Venous thromboembolismDuring the initial hospitalization, an average of 7 daysSymptomatic, objectively confirmed fatal and non-fatal hospital-acquired venous thromboembolism, including symptomatic distal and proximal deep vein thrombosis and pulmonary embolism during hospitalization
Length of hospital staywithin 90 days of initial hospital admissionLength of hospital stay, defined as the time/date of discharge minus time/date of admission at the hospital ward
Subsequent hospitalizationsWithin 90 days of initial hospital admissionSubsequent hospitalization, defined as hospital readmissions
Patient autonomy in the activities of daily livingAt discharge (an average of 7 days after initial hospital admission) and at 90 days after admissionPatient autonomy in the activities of daily living as assessed by the modified Barthel Index

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026